タキザワ　マキコ   TAKIZAWA Makiko   滝沢　牧子    所属   埼玉医科大学  医学部 総合医療センター　医療安全管理学    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.
掲載誌名	正式名：International journal of hematology ISSNコード：0925-5710/1865-3774
掲載区分	国内
出版社	SPRINGER JAPAN KK
巻・号・頁	103(2),219-26頁
著者・共著者	Takeki Mitsui,Hiromi Koiso,Hirotaka Nakahashi,Akio Saitoh,Hiroaki Shimizu,Takuma Ishizaki,Yoshiyuki Ogawa,Makiko Takizawa,Akihiko Yokohama,Takayuki Saitoh,Takahiro Jinbo,Hidemi Ogura,Hiroshi Handa,Morio Sawamura,Tohru Sakura,Masamitsu Karasawa,Hirokazu Murakami,Yoshihisa Nojima,Norifumi Tsukamoto
発行年月	2016/02
概要	The incidence of chronic lymphocytic leukemia (CLL) is low in Japan. The clinical course ranges from very indolent to rapidly progressive. Recently, several reports have indicated that mutation of the splicing factor 3b, subunit 1 (SF3B1) gene in CLL is predictive of a poor prognosis. Here, we investigated the SF3B1 mutational status of Japanese CLL patients and clarified the association between SF3B1 mutational status and prognostic factors. One hundred and two patients that were referred to our institutions between 1999 and 2013 were enrolled. Mutation analysis of SF3B1 (n = 87) and of the immunoglobulin heavy chain gene (IGHV) (n = 102) was performed at diagnosis. FISH analysis of del(11)(q22) was performed for 17 patients. Seven patients have SF3B1 mutation (8.0 %: K700E, 5/7; G742D, 1/7 and Y623C, 1/7). The median survival times for patients with mutated and non-mutated SF3B1 were 53 and 130 months, respectively. Overall survival of the mutated SF3B1 group was significantly lower than that of the non-mutated group (p = 0.0187). No relationship was observed between IGHV mutational status and SF3B1 mutation. There was no patient with SF3B1 mutation in the IGHV1-69 population (0/2). In conclusion, mutation of SF3B1 at diagnosis in Japanese CLL patients is predictive of a poor prognosis.
DOI	10.1007/s12185-015-1912-z
PMID	26588928